ASTRO Names New Honorary Members

Publication
Article
OncologyONCOLOGY Vol 16 No 9
Volume 16
Issue 9

Officials from the American Society for Therapeutic Radiology and Oncology (ASTRO) have announced that Ann Barrett, md, of the University of East Anglia in the United Kingdom, and John J. Curry, of the American College of Radiology, have

Officials from the American Society for Therapeutic Radiology and Oncology (ASTRO)have announced that Ann Barrett, md, of the University of East Anglia in theUnited Kingdom, and John J. Curry, of the American College of Radiology, havebeen chosen to receive honorary memberships—the highest honor ASTRO bestowsupon distinguished cancer researchers and leaders in disciplines other thanradiation oncology, radiation physics, and radiobiology.

"Honorary membership is reserved for distinguished men and women whohave made significant contributions to the objectives of our society," saidASTRO chair David A. Larson, phd, md, facr. "I am honored to present thisaward to two outstanding individuals who, in the course of their careers, havegreatly advanced the specialty of radiation oncology."

Distinguished Honorees

Dr. Barrett was a founding member of the European Society for TherapeuticRadiology and Oncology, serving as that organization’s president from 1997 to1999. Recognized as an international authority on pediatric radiation oncology,she is presently the Foundation Chair of Oncology at the University of EastAnglia, and is working to develop that university’s new medical school.

Mr. Curry is known for a lifetime of promoting excellence in radiationtherapy and research. In 1984, he became executive director of the AmericanCollege of Radiology, and under his leadership, the organization has become apowerful voice in setting standards, and developing appropriateness guidelinesand accreditation programs for both diagnostic and therapeutic radiology.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content